Press Enter to search · Esc to close
A new scoping review reframes obesity as an organelle-level problem — and points to the levers, lifestyle and pharmacological, that actually shift mitochondrial function.
Two fresh syntheses sharpen the picture of how the most-talked-about GLP-1 protects the heart — and where the evidence still has gaps.
A large NHANES analysis suggests the American Heart Association's updated checklist doesn't just predict heart trouble — it lines up with how fast your body is actually aging.
A new Korean cohort study ranks which of the eight cardiovascular health pillars move the biological-age needle most — and the answer differs by sex.
The American Heart Association's updated 0–100 cardiovascular score now includes sleep — and new French cohort data show how few adults actually land in the 'high' zone.
Two 2025 papers move biological-age measurement closer to the clinic — one builds a risk score from routine bloodwork, the other names a druggable target in the aging heart.
A global expert consensus on exercise for healthy aging arrives alongside trials testing very different anti-frailty levers — from blueberries and protein to a growth-hormone-releasing peptide. Together they reframe frailty as something we can actively push back on.
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
A new narrative review argues that stacking moderate-vigorous aerobic work with resistance training delivers cardiovascular gains neither modality hits alone. A parallel Spanish trial asks what to do when frailty rules out the barbell.